| Name | Title | Contact Details |
|---|
Kaléo is dedicated to inventing, manufacturing and commercializing life-transforming products that empower patients and families to live fuller, bolder lives. We are committed to developing solutions that support the healthcare provider-patient relationship, improving access to our products.
Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.
GlaxoSmithKline USA is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MedSym Solutions is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sharn Inc is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.